MCID: PRS045
MIFTS: 45

Prostatic Hypertrophy malady

Category: Reproductive diseases

Aliases & Classifications for Prostatic Hypertrophy

About this section

Aliases & Descriptions for Prostatic Hypertrophy:

Name: Prostatic Hypertrophy 11 13 68
Benign Prostatic Hypertrophy 68
 
Prostatic Hyperplasia 68

Classifications:



External Ids:

Disease Ontology11 DOID:11132

Summaries for Prostatic Hypertrophy

About this section
MalaCards based summary: Prostatic Hypertrophy, also known as benign prostatic hypertrophy, is related to prostatitis and hole retinal cyst, and has symptoms including prostatism and prostatism. An important gene associated with Prostatic Hypertrophy is KLK3 (Kallikrein Related Peptidase 3), and among its related pathways are Aromatase Inhibitor Pathway (Breast Cell), Pharmacodynamics and Ovarian Infertility Genes. The drugs finasteride and leuprolide have been mentioned in the context of this disorder. Affiliated tissues include prostate, heart and kidney, and related mouse phenotypes are digestive/alimentary and cardiovascular system.

Related Diseases for Prostatic Hypertrophy

About this section

Diseases related to Prostatic Hypertrophy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 119)
idRelated DiseaseScoreTop Affiliating Genes
1prostatitis10.9
2hole retinal cyst10.3AR, KLK3
3prostate cancer10.3
4bartholin's gland benign neoplasm10.3ESR1, PGR
5dystonia-parkinsonism, x-linked10.3AR, CYP19A1
6cardiovascular organ benign neoplasm10.3ESR1, PGR
7appendix leiomyoma10.3ESR1, PGR
8bronchus adenoma10.3ESR1, PGR
9glioma10.3ESR1, PGR
10ovarian benign neoplasm10.3ESR1, PGR
11plexiform neurofibroma10.3ESR1, PGR
12paranasal sinus disease10.3ESR1, PGR
13x-linked leigh syndrome10.3AR, ESR1
14deafness, autosomal recessive 2110.3ESR1, PGR
15ulceroglandular tularemia10.3AR, ESR1
16colon signet ring adenocarcinoma10.3AR, KLK3
17cervical lymphoepithelioma-like carcinoma10.2ESR1, PGR
18histiocytic and dendritic cell cancer10.2ESR1, PGR
19atypical lipomatous tumor10.2ESR1, PGR
20pediatric intraocular retinoblastoma10.2ESR1, PGR
21congenital disorder of glycosylation, type ic10.2ESR1, PGR
22intestinal perforation10.2ESR1, PGR
23borderline personality disorder10.2AR, CYP19A1
24perlman syndrome10.2ESR1, PGR
25bladder adenocarcinoma10.2ESR1, PGR
26biemond syndrome10.2CYP19A1, PGR
27vulva basal cell carcinoma10.2ESR1, PGR
28villoglandular endometrial endometrioid adenocarcinoma10.2ESR1, PGR
29vaginal adenosarcoma10.2ESR1, PGR
30panophthalmitis10.2CYP19A1, PGR
31glioblastoma mesenchymal subtype10.2AR, CYP19A1, KLK3
32intraneural perineurioma10.2ESR1, PGR
33paraphimosis10.2ESR1, PGR
34skin hemangioma10.2AR, CYP19A1, KLK3
35malignant teratocarcinosarcoma10.2ALPP, AR
36central nervous system mature teratoma10.2ESR1, PGR
37biliary tract neoplasm10.2ESR1, KLK3, PGR
38benign fibrous mesothelioma10.2EGF, ESR1
39leukoencephalopathy with ataxia10.2AR, CYP19A1
40her2-receptor negative breast cancer10.2CYP19A1, ESR1, PGR
41necrobiosis lipoidica10.2ESR1, KLK3, PGR
42benign shuddering attacks10.2AR, CYP19A1, ESR1
43acute thyroiditis10.2CYP19A1, ESR1, PGR
44perinatal jaundice due to hepatocellular damage10.1CYP19A1, ESR1, PGR
45intraventricular meningioma10.1AR, SRY
46bowman's membrane folds or rupture10.1AR, PGR
47glycerol kinase deficiency, adult form10.1CYP19A1, ESR1, PGR
48nervous system hibernoma10.1AR, ESR1, PGR
49breast duct papilloma10.1CYP19A1, ESR1, PGR
50anal neuroendocrine tumor10.1AR, ESR1, PGR

Comorbidity relations with Prostatic Hypertrophy via Phenotypic Disease Network (PDN):

(show top 50)    (show all 52)
Acute CystitisAcute Kidney Failure
AnthracosisAsbestosis
Bladder DiseaseBladder Neck Obstruction
Chronic Kidney FailureChronic Myocardial Ischemia
Cystitis CysticaCystitis
First-Degree Atrioventricular BlockGeneralized Atherosclerosis
GoutHydronephrosis
Interstitial CystitisIschemic Heart Disease
Kidney DiseaseLeft Bundle Branch Hemiblock
Lipoma of Spermatic CordLow Compliance Bladder
Nephrolithiasis, Type INeurogenic Bladder
Parkinson Disease, Late-OnsetPelvic Varices
Pinta DiseasePneumoconiosis
Postinflammatory Pulmonary FibrosisProstate Cancer
Prostate Carcinoma in SituBalanoposthitis
Epididymo-OrchitisInfected Hydrocele
Penile DiseasePeyronie's Disease
Prostate CalculusProstate Disease
ProstatitisProstatocystitis
SpermatoceleRenal Pelvis Carcinoma
Right Bundle Branch BlockSilicosis
Ureter CancerUreterolithiasis
Urethral Benign NeoplasmUrethral Calculus
Urethral StrictureUrethritis
Urinary Bladder CancerUrinary Tract Obstruction

Graphical network of the top 20 diseases related to Prostatic Hypertrophy:



Diseases related to prostatic hypertrophy

Symptoms & Phenotypes for Prostatic Hypertrophy

About this section

UMLS symptoms related to Prostatic Hypertrophy:


prostatism

MGI Mouse Phenotypes related to Prostatic Hypertrophy according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053818.3AR, CD36, CYP19A1, EGF, ESR1, FGF8
2MP:00053858.2ADRA1A, AR, CD36, CYP19A1, ESR1, FGF8
3MP:00053698.1ADRA1A, AR, CD36, CYP19A1, ESR1, FGF8
4MP:00053867.9ADRA1A, AR, CD36, CYP19A1, ESR1, FGF8
5MP:00053797.9AR, CD36, CYP19A1, EGF, ESR1, FGF8
6MP:00053677.8ADRA1A, AR, CD36, CYP19A1, ESR1, FGF8
7MP:00053877.5AR, CD36, CYP19A1, EGF, ESR1, FGF8

Drugs & Therapeutics for Prostatic Hypertrophy

About this section

Drugs for Prostatic Hypertrophy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 106)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Tamsulosinapproved, investigationalPhase 4, Phase 3, Phase 1159106133-20-4129211
Synonyms:
(R)-5-(2-((2-(2-Ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide
106133-20-4
5-(2-((2-(2-ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide
5-[(2R)-2-[2-(2-ethoxyphenoxy)ethylamino]propyl]-2-methoxybenzenesulfonamide
5-[(2R)-2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl]-2-methoxybenzenesulfonamide
5-[2-[2-(2-Ethoxyphenoxy)ethylamino]propyl]-2-methoxy-benzenesulfonamide
5-[2-[2-(2-ethoxyphenoxy)ethylamino]propyl]-2-methoxy-benzenesulfonamide
5-{(2R)-2-[(2-{[2-(ethyloxy)phenyl]oxy}ethyl)amino]propyl}-2-(methyloxy)benzenesulfonamide
AC1L2V76
BIDD:GT0261
C07124
C20H28N2O5S
CHEBI:9398
CHEMBL836
CID129211
D08560
DB00706
FT-0082894
Flomax
Flomax (TN)
Flowmax
HMS2090P15
 
Harnal
LS-31578
MolPort-003-850-388
NCGC00167442-01
Omnic
Pradif
STK626950
TAMSULOSIN
Tamsolusin
Tamsulon
Tamsulon (TN)
Tamsulosin
Tamsulosin (INN)
Tamsulosin [INN:BAN]
Tamsulosina
Tamsulosina [INN-Spanish]
Tamsulosine
Tamsulosine [INN-French]
Tamsulosinum
Tamsulosinum [INN-Latin]
UNII-G3P28OML5I
YM-617
tamsulosin
2
Alfuzosinapproved, investigationalPhase 4, Phase 3, Phase 25281403-80-72092
Synonyms:
(±)-N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furamide
128707-53-9
81403-68-1 (hydrochloride)
81403-80-7
86163-78-2
AB00514667
AC1L1CWF
Alfusosine
Alfuzosin
Alfuzosin (INN)
Alfuzosin [INN:BAN]
Alfuzosina
Alfuzosina [Spanish]
Alfuzosine
Alfuzosine [French]
Alfuzosinum
Alfuzosinum [Latin]
BPBio1_000357
BRD-A09056319-001-02-2
BRD-A09056319-003-03-6
BSPBio_000323
BSPBio_002646
Bio-0003
C19H27N5O4
CHEBI:51141
CHEMBL709
CID2092
CPD000466340
D07124
DB00346
HMS1922P11
HMS2051I10
HMS2093O06
HSDB 7290
 
KBio3_001866
KBioGR_001616
L001317
LS-70106
MLS000759449
MLS001424027
MolPort-003-666-623
N-(3-((4-Amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-2-furancarboxamide
N-[3-[(4-amino-6,7-dimethoxy-quinazolin-2-yl)- methyl-amino]propyl] tetrahydrofuran- 2-carboxamide
N-[3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]propyl]oxolane-2-carboxamide
N-{3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)(methyl)amino]propyl}tetrahydrofuran-2-carboxamide
NCGC00095152-01
NCGC00095152-02
NCGC00095152-03
NCGC00095152-04
NCGC00095152-05
Prestwick0_000322
Prestwick1_000322
Prestwick2_000322
Prestwick3_000322
SAM001246638
SL 77-499
SL 77499
SMR000466340
SPBio_000429
SPBio_002244
SPECTRUM1505263
STK643675
Spectrum2_000505
Spectrum3_001063
Spectrum4_001208
Spectrum5_000817
UNII-90347YTW5F
Xatral (TN)
alfuzosin
alphuzosine
3
DoxazosinapprovedPhase 4, Phase 35874191-85-83157
Synonyms:
1-(4-Amino-6,7-Dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl)piperazin
1-(4-Amino-6,7-dimethoxy-2-chinazolinyl)-4-(2,3-dihydro-1,4-benzodioxixin-2-ylcarbonyl)piperazin
1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-[4-(1,4-benzodioxan-2-yl)carpiperazin-1-yl)]-6,7-dimethoxyquinazoline mesylate
2-[4-(2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl)piperazin-1-yl]-6,7-bis(methyloxy)quinazolin-4-amine
2-[4-(2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine
2-{4-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]piperazin-1-yl}-6,7-dimethoxyquinazolin-4-amine
74191-85-8
77883-43-3 (mesylate)
AC-11062
AC1L1FAT
AC1Q470P
AC1Q4EXN
AKOS001681453
BPBio1_000963
BRD-A13188892-066-03-3
BSPBio_000875
C06970
C23H25N5O5
CHEBI:4708
CHEMBL707
CID3157
CPD000097306
Cardura XL (TN)
Cardura-1
Cardura-2
Cardura-4
ChemDiv2_005017
D07874
D9815_SIGMA
DB00590
 
Doxazosin (INN)
Doxazosin [INN:BAN]
Doxazosin mesilate
Doxazosina
Doxazosina [Spanish]
Doxazosine
Doxazosine [French]
Doxazosinum
Doxazosinum [Latin]
HMS1383E01
HMS2090C20
I06-1346
IDI1_003732
L000738
LS-110228
Lopac0_000474
MolPort-001-684-491
NCGC00018158-06
NCGC00089775-02
Normothen
Oprea1_259518
Prestwick0_000858
Prestwick1_000858
Prestwick2_000858
Prestwick3_000858
SAM002589981
SPBio_002796
UK 33274
UK-33274
UNII-NW1291F1W8
[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(2,3-dihydro-1,4-benzodioxin-3-yl)methanone
doxazosin
4
MethyltestosteroneapprovedPhase 4, Phase 3, Phase 256358-18-46010
Synonyms:
17(alpha)-Methyl-delta(4)-androsten-17(beta)-ol-3-one
17-Methyltestosterone
17-beta-Hydroxy-17-methylandrost-4-en-3-one
17-methyltestosterone
17alpha-Methyl-3-oxo-4-androsten-17beta-ol
17alpha-Methyl-delta(4)-androsten-17beta-ol-3-one
17alpha-Methyltestosterone
17alpha-methyl-delta-androsten-17beta-ol-3-one
17alpha-methyltestosterone
 
17beta-Hydroxy-17-methylandrost-4-en-3-one
17α-methyl-Δ4-androsten-17β-ol-3-one
17α-methyltestosterone
4-Androstene-17alpha-methyl-17beta-ol-3-one
Android
Methyltestosterone
Methyltestosteronum
Metiltestosterona
NSC-9701
Testred
Virilon
5
MivacuriumapprovedPhase 410106791-40-6, 133814-19-45281042
Synonyms:
(R)-1,2,3,4-Tetrahydro-2-(3-hydroxypropyl)-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxybenzyl)isoquinolinium chloride, (E)-4-octenedioate (2:1)
106791-40-6
106861-44-3
133814-19-4
AC1NQXXZ
AC1NQXZZ
BW B109OU dichloride
BW-B1090U
BW-B109OU
BWB109OU
C07550
C58H80N2O14
CHEMBL984
CID5281042
CID5281080
Chlorure de mivacurium
 
Chlorure de mivacurium [French]
Cloruro de mivacurio
Cloruro de mivacurio [Spanish]
D00763
DB01226
LS-172022
MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER
MIVACURIUM CHLORIDE
Mivacron
Mivacron (TN)
Mivacurii chloridum
Mivacurii chloridum [Latin]
Mivacurium
Mivacurium chloride (USAN/INN)
Mivacurium chloride [USAN:INN:BAN]
NCGC00167469-01
bis[3-[(1R)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] (E)-oct-4-enedioate
bis[3-[(1R)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] (E)-oct-4-enedioate dichloride
6
SilodosinapprovedPhase 423160970-54-7
Synonyms:
KAD 3213
 
KMD 3213
Rapaflo
Urief
7
RocuroniumapprovedPhase 4283119302-91-9, 143558-00-3441290
Synonyms:
(2beta,3alpha,5alpha,16beta,17beta)-17-acetoxy-16-(1-allylpyrrolidinium-1-yl)-3-hydroxy-2-(morpholin-4-yl)androstane
143558-00-3
AC1L9AWM
BIDD:GT0360
C07556
CHEBI:8884
CID441290
 
DB00728
Esmeron
HMS2090E03
NCGC00167433-01
Rocuronium
Rocuronium bromide
Zemuron
[(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-3-hydroxy-10,13-dimethyl-2-morpholin-4-yl-16-(1-prop-2-enylpyrrolidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate
8
DihydrotachysterolapprovedPhase 41867-96-95281010, 5311071
Synonyms:
(1S,3E,4S)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylcyclohexan-1-ol
(1S,3E,4S)-3-[(2E)-2-[(3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylcyclohexan-1-ol
(3E)-3-[(2E)-2-[1-[(E)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylcyclohexan-1-ol
(3S,5E,7E,10S,22E)-9,10-secoergosta-5,7,22-trien-3-ol
(3Z)-3-[(2E)-2-[1-[(E)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylcyclohexan-1-ol
67-96-9
9,10-Secoergosta-5,7,22-trien-3beta-ol
A.T. 10
AC1NQXW4
AC1NS4C8
AC1NSJXZ
AC1NWALO
AT 10
Anti-tetany substance 10
Antitanil
C06957
C28H46O
CHEBI:4591
CID5281010
CID5311071
CID5353584
CID5702045
Calcamine
D9257_FLUKA
D9257_SIGMA
DB01070
DHT
DHT2
 
Dht Intensol
Dht(sub 2)
Dichystrolum
Dihidrotaquisterol
Dihidrotaquisterol [INN-Spanish]
Dihydral
Dihydrotachysterol [INN:BAN:JAN]
Dihydrotachysterol(sub 2)
Dihydrotachysterolum
Dihydrotachysterolum [INN-Latin]
Diidrotachisterolo
Diidrotachisterolo [DCIT]
Dygratyl
EINECS 200-672-7
HMS502L11
HSDB 3314
Hytakerol
IDI1_000869
LMST03010056
LS-148512
MolPort-003-941-198
NCGC00166147-01
NCGC00166147-02
Parterol
ST075187
Tachyrol
Tachystin
Vitamin D4
dihydrotachysterol
9
Testosteroneapproved, investigationalPhase 4, Phase 3, Phase 256358-22-06013
Synonyms:
(+)-testosterone
(+-)-8-iso-testosterone
(+-)-retrotestosterone
(+-)-testosterone
(17b)-17-hydroxy-androst-4-en-3-one
(17beta)-17-Hydroxyandrost-4-en-3-one
(8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one
13-Iso-testosterone
17-Hydroxy-(17-beta)-androst-4-en-3-one
17-Hydroxy-(17beta)-androst-4-en-3-one
17-Hydroxy-10,13-dimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3-one
17-Hydroxy-D4-androsten-3-one
17-Hydroxy-androst-4-en-3-one
17-beta-Hydroxy-delta(sup 4)-androsten-3-one
17-beta-Hydroxyandrost-4-en-3-one
17?-Hydroxy-4-androsten-3-one
17a-Hydroxy-(13a)-androst-4-en-3-one
17a-Hydroxy-13a-androst-4-en-3-one
17a-Hydroxy-14b-androst-4-en-3-one
17a-Hydroxy-androst-4-en-3-one
17b-Hydroxy-(10a)-androst-4-en-3-one
17b-Hydroxy-(13a)-androst-4-en-3-one
17b-Hydroxy-(8a)-androst-4-en-3-one
17b-Hydroxy-(8a,10a)-androst-4-en-3-one
17b-Hydroxy-(9b)-androst-4-en-3-one
17b-Hydroxy-(9b,10a)-androst-4-en-3-one
17b-Hydroxy-13a-androst-4-en-3-one
17b-Hydroxy-8a-androst-4-en-3-one
17b-Hydroxy-D4-androsten-3-one
17b-Hydroxy-androst-4-en-3-on
17b-Hydroxy-androst-4-en-3-one
17b-Hydroxyandrost-4-en-3-one
17b-Hydroxyandrost-4-ene-3-one
17b-Testosterone
17b-hydroxy-4-androsten-3-one
17beta-Hydroxy-3-oxo-4-androstene
17beta-Hydroxy-4-androsten-3-one
17beta-Hydroxy-delta(sup4)-androsten-3-one
17beta-Hydroxyandrost-4-en-3-one
17beta-Hydroxyandrost-4-ene-3-one
17beta-hydroxy-4-androsten-3-one
4-Androsten-17?-ol-3-one
4-Androsten-17beta-ol-3-one
4-Androsten-3-one-17b-ol
4-androsten-17β-ol-3-one
4-androstene-17beta-ol-3-one
46923_FLUKA
46923_RIEDEL
58-22-0
7-beta-Hydroxyandrost-4-en-3-one
8-Iso-testosterone
9b,10a-Testosterone
9b-Testosterone
AA 2500
AC-14899
AC1L1LM0
Andriol
Andro
Andro 100
Andro L.A. 200
AndroGel
Androderm
Androderm (TN)
Androgel
Androgel (TN)
Android 10
Android 25
Android 5
Androlin
Andronaq
Andronate 100
Andronate 200
Andropatch
Andropository 200
Androsorb
Androst-4-en-17b-ol-3-one
Androst-4-en-17beta-ol-3-one
Androst-4-ene-17b-ol-3-one
Andrusol
Andryl 200
B5DEE83F-632B-48A1-A0ED-A51E7F13DF2E
BIDD:ER0555
BIM-0061761.0001
Beta Testosterone
Bio-0678
Bio-T-Gel
C00535
CCRIS 574
CDB 111C
CHEBI:17347
CHEMBL386630
CID6013
CMC_13449
COL 1621
CP 601B
CPD000058344
Cristerona T
Cristerone T
D00075
D4-Androsten-17b-ol-3-one
DB00624
Dea No. 4000
Delatest
Delatestryl
Depo-Testadiol
Depo-Testosterone
Depo-Testosterone Cypionate
Depotest
EINECS 200-370-5
Epitestosteron
Everone 200
Geno-Cristaux Gremy
Geno-cristaux Gremy
Geno-cristaux gremy
HMS2052N11
HSDB 3398
Halotensin
Homosteron
Homosterone
 
Intrinsa
LMST02020002
LS-148813
LibiGel
Libigel
Lumitestosteron
MLS000563091
MLS001032098
MLS001306401
MLS002174283
Malerone
Malestrone
Malestrone (amps)
Malogen in Oil
Malogen, Aquaspension Injection
Malogen, aquaspension injection
Mertestate
Metandren
Methyltestosterone
MolPort-002-506-901
NCGC00091018-01
NSC 9700
Neo-Hombreol F
Neo-Testis
Neo-testis
Neotestis
Oreton
Oreton F
Oreton Methyl
Oreton-F
Orquisteron
Perandren
Percutacrine Androgenique
Percutacrine androgenique
Primotest
Primoteston
Rac-17b-hydroxy-(13a)androst-4-en-3-one
Rac-17b-hydroxy-(8a)-androst-4-en-3-one
Rac-17b-hydroxy-(9b,10a)androst-4-en-3-one
Rac-17b-hydroxy-androst-4-en-3-one
Relibra
Retrotestosterone
S00309
S2033_Selleck
SAM001246921
SMR000058344
SMR001261453
Scheinpharm Testone-Cyp
Striant
Striant (TN)
Sustanon
Sustanone
Sustason 250
Synandrol F
T-Cypionate
T1500_SIGMA
T5411_FLUKA
T5411_SIGMA
TES
Teslen
Testamone 100
Testandrone
Testaqua
Testiculosterone
Testim
Testim (TN)
Testobase
Testoderm
Testoderm Tts
Testogel
Testoject-50
Testolent
Testolin
Testopel Pellets
Testopropon
Testosteroid
Testosteron
Testosterona
Testosterona [INN-Spanish]
Testosterone
Testosterone (JAN/USP)
Testosterone Cypionate
Testosterone Enanthate
Testosterone Hydrate
Testosterone [Androgenic steroids, anabolic]
Testosterone [INN:BAN]
Testosterone and its esters
Testosterone hydrate
Testosterone solution
Testosteronum
Testosteronum [INN-Latin]
Testostosterone
Testostérone
Testoviron
Testoviron Schering
Testoviron T
Testoxyl
Testred
Testred Cypionate 200
Testrin-P.A
Testro AQ
Testro Aq
Testrone
Testryl
Tostrelle
Tostrex
Trans-Testosterone
UNII-3XMK78S47O
Viatrel
Virilon
Virilon IM
Virormone
Virosterone
ZINC06500184
beta testosterone
delta(sup 4)-Androsten-17(beta)-ol-3-one
delta4-Androsten-17beta-ol-3-one
delta4-androsten-17b-ol-3-one
testosterone
trans-Testosterone
10
Dutasterideapproved, investigationalPhase 4, Phase 3, Phase 2114164656-23-9152945, 6918296
Synonyms:
(1S,3aS,3bS,5aR,9aR,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide
(1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide
(5.alpha.,17.beta.)-N-{2,5 bis(trifluoromethyl)phenyl}-3-oxo-4-azaandrost-1-ene-17-carboxamide
(5alpha,17beta)-N-(2,5-Bis(trifluoromethyl)phenyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide
164656-23-9
AC1L49EM
AC1OCF98
Avodart
Avodart (TN)
Avodart, Dutasteride
Avolve
Bio-0167
C27H30F6N2O2
CHEBI:132773
CHEMBL1200969
CHEMBL283245
CID152945
CID6918296
CID9914880
D03820
 
DB01126
Duagen
Dutasteride
Dutasteride (JAN/USAN/INN)
Dutasteride [USAN]
FT-0080365
GG 745
GG-745
GI 198745
GI-198745
GI-198745X
LS-173584
MolPort-003-666-660
MolPort-003-847-041
N-[2,5-bis(trifluoromethyl)phenyl]-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide
NSC740477
S1202_Selleck
UNII-O0J6XJN02I
ZINC03932831
alpha,alpha,alpha,Alpha',alpha',alpha'-hexafluoro-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxy-2',5'-xylidide
alpha,alpha,alpha,alpha',alpha',alpha'-Hexafluoro-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxy-2',5'-xylidide
11
MirabegronapprovedPhase 495223673-61-8
Synonyms:
 
Myrbetriq
12
DihydrotestosteroneillicitPhase 415521-18-610635
Synonyms:
17-Hydroxy-androstan-3-one
17-Hydroxyandrostan-3-one
17b-Hydroxy-3-androstanone
17beta-Hydroxy-5alpha-androstan-3-one
17beta-Hydroxy-5alpha-androstane-3-one
17beta-Hydroxyandrostan-3-one
17beta-hydroxy-5alpha-androstan-3-one
17β-hydroxy-3-oxo-5α-androstanone
17β-hydroxy-5α-androstan-3-one
4,5a-Dihydrotestosterone
4-Dihydrotestosterone
5-a-Androstanolone
5-alpha-Androstanolone
5A-Androstan-3-on-17B-ol
5B-Androstan-3-on-17B-ol
5a-Androstan-17b-ol-3-one
5a-Dihydrotestosterone
5alpha-Dihydrotestosterone
 
5alpha-androstan-17beta-ol-3-one
5α-DHT
Anaboleen
Anabolex
Andractim
Androlone
Androstalone
Androstanolone
Cristerona MB
DHT
Dihydrotestosteron
Dihydrotestosterone
Dihydrotestostérone
Drolban
Neodrol
Proteina
Protona
Stanaprol
Stanolone
Stanorone
13Adrenergic AntagonistsPhase 4, Phase 3, Phase 21573
14Adrenergic alpha-AntagonistsPhase 4, Phase 3, Phase 2739
15Adrenergic alpha-1 Receptor AntagonistsPhase 4, Phase 3, Phase 2480
16Cholinergic AgentsPhase 4, Phase 3, Phase 23992
17Neurotransmitter AgentsPhase 4, Phase 3, Phase 218340
18Neuromuscular AgentsPhase 4, Phase 3, Phase 21180
19Adrenergic AgentsPhase 4, Phase 3, Phase 25352
20AnestheticsPhase 49596
21Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 223689
22Steroid Synthesis InhibitorsPhase 4, Phase 3, Phase 1, Phase 21763
23Adrenergic AgonistsPhase 43027
24Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 3, Phase 1, Phase 213168
25Antihypertensive AgentsPhase 4, Phase 34207
26Testosterone undecanoatePhase 4, Phase 3, Phase 2563
27
Testosterone enanthatePhase 4, Phase 3, Phase 2563315-37-79416
Synonyms:
17-((1-Oxoheptyl)oxy)androst-4-en-3-one
17-Hydroxyandrost-4-en-3-one, 17-heptanoate
17-Hydroxyandrost-4-en-3-one, 17-heptanoic acid
17beta-Enanthoxyandrost-4-en-3-one
17beta-Hydroxyandrost-4-en-3-one enanthate
4-Androsten-17beta-ol-3-one 17-enanthate
4-Androsten-3-one 17beta-enanthate
Androgyn L.A.
Andropository
Androtardyl
Atlatest
DEA No. 4000
DePatestrye
Delatest
Delatestryl
Depo-Testro Med
Ditate
Durathate
Everone
 
Exten test
Malogen L.A.
Malogen L.A.200
Orquisteron-E
Primotestone
Reposo TMD
Testanthate
Testate
Testenate
Testinon
Testoenant
Testonenant
Testosterone 17-enanthate
Testosterone 17beta-heptanoate
Testosterone 17beta-heptanoic acid
Testosterone enantate
Testosterone heptoate
Testosterone heptoic acid
Testosterone heptylate
Testosterone oenanthate
Testostroval
28Testosterone 17 beta-cypionatePhase 4, Phase 3, Phase 2563
29Antineoplastic Agents, HormonalPhase 4, Phase 25592
30HormonesPhase 4, Phase 3, Phase 1, Phase 214415
31Muscarinic AntagonistsPhase 41166
32Neuromuscular Blocking AgentsPhase 4429
33Cholinergic AntagonistsPhase 41706
34
AtracuriumPhase 48064228-79-147319
Synonyms:
2,2'-{pentane-1,5-diylbis[oxy(3-oxopropane-3,1-diyl)]}bis[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolinium]
5-[3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoyloxy]pentyl 3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoate
64228-79-1
64228-81-5 (besylate)
AB00514743
AC1L2HUF
AC1Q67HR
Atracurium
Atracurium Dibesylate
BPBio1_000011
BRN 1523633
BSPBio_000009
 
C07548
C53H70N2O12
CHEBI:2914
CHEMBL1360
CID47319
DB00732
HMS2090I21
LS-86151
MolPort-005-932-641
Prestwick1_000005
Prestwick2_000005
Prestwick3_000005
SPBio_001930
UNII-2GQ1IRY63P
35Solifenacin succinatePhase 4116242478-38-2
36Neuromuscular Nondepolarizing AgentsPhase 4254
37Hormone AntagonistsPhase 4, Phase 3, Phase 1, Phase 213180
38AndrogensPhase 4, Phase 3, Phase 21321
39Anabolic AgentsPhase 4, Phase 2513
405-alpha Reductase InhibitorsPhase 4, Phase 3, Phase 1, Phase 2167
41Adrenergic beta-3 Receptor AgonistsPhase 4102
42Adrenergic beta-AgonistsPhase 41714
43
AcetylcholineapprovedPhase 3, Phase 280551-84-3187
Synonyms:
ACh
Acetyl choline ion
Acetylcholine Chloride
Acetylcholine cation
 
Acetylcholinium: acetyl-Choline
Choline acetate
Choline acetate (ester)
O-Acetylcholine
acetylcholine chloride
44
FinasterideapprovedPhase 3, Phase 1, Phase 26798319-26-757363
Synonyms:
(1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-tert-butyl-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide
(4aR,4bS,6aS,7S,9aS,9bS,11aR)-N-(1,1-dimethylethyl)-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
(4aR,4bS,6aS,7S,9aS,9bS,11aR)-N-(tert-butyl)-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
(5alpha,17beta)-(1,1-Dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide
17beta-(N-tert-butylcarbamoyl)-4-aza-5 alpha-androst-1-en-3-one
34202_FLUKA
34202_RIEDEL
98319-26-7
AB00513901
AC1L1MUF
AC1Q5L2C
Andozac
BPBio1_001027
BRD-K01095011-001-03-5
BRN 4269024
BSPBio_000933
C23H36N2O2
CCRIS 7438
CHEBI:5062
CHEMBL710
CID57363
CPD000466304
Cahill May Roberts Brand of Finasteride
Chibro Proscar
Chibro-Proscar
Chibro-proscar
D00321
D018120
DB01216
DB07774
Eucoprost
F1293_SIGMA
FIT
FT-0082891
Finasterida
Finasterida [INN-Spanish]
Finasteride (USP/INN)
Finasteride [USAN:INN:BAN]
Finasteridum
Finasteridum [INN-Latin]
Finastid
Finpecia
Frosst Iberica Brand of Finasteride
HMS1570O15
HMS2051F09
 
HMS2090G22
HSDB 6793
KS-1058
L-652,931
LS-7397
Lipha Brand of Finasteride
MK 0906
MK 906
MK-0906
MK-906
MK906
MLS000759404
MLS001165768
MLS001424046
MSD Brand of Finasteride
MSD Chibropharm Brand of Finasteride
Merck Brand 1 of Finasteride
Merck Brand 2 of Finasteride
Merck Frosst Brand 1 of Finasteride
Merck Frosst Brand 2 of Finasteride
Merck Sharp & Dhome Brand 2 of Finasteride
Merck Sharp & Dohme Brand 1 of Finasteride
MolPort-002-500-272
N-(2-Methyl-2-propyl)-3-oxo-4-aza-5-alpha-androst-1-ene-17-beta-carboxamide
N-(2-methyl-2-propyl)-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide
N-tert-Butyl-3-oxo-4-aza-5alpha-androst-1-en-17beta-carboxamide
N-tert-Butyl-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide
Prestwick0_000717
Prestwick1_000717
Prestwick2_000717
Prestwick3_000717
Propecia
Propecia (TN)
Propeshia
Proscar
Proscar (TN)
Proscar, Propecia, Finasteride
Prostide
S1197_Selleck
SAM001246541
SMR000466304
SPBio_002854
UNII-57GNO57U7G
YM-152
ZINC03782599
finasteride
45
Cetrorelixapproved, investigationalPhase 365120287-85-616129715, 25074887
Synonyms:
120287-85-6
Ac-D-Nal(2)-D-Phe(pCl)-D-Pal(3)-Ser-Tyr-D-Cit-Leu-Arg-Pro-D-Ala-NH2
CHEBI:59224
CHEMBL1200490
Cetrorelix
Cetrorelix (INN)
Cetrorelixum
 
Cetrorelixum [INN-Latin]
Cetrotide (TN)
D07665
HS-2008
N-acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-L-tyrosyl-N5-carbomoyl-D-ornithyl-L-leucyl-L-prolyl-D-alaninamide
N-acetyl-3-(naphthalen-2-yl)-D-alanyl-4-chloro-D-phenylalanyl-3-(pyridin-3-yl)-D-alanyl-L-seryl-L-tyrosyl-N(5)-carbamoyl-D-ornithyl-L-leucyl-L-arginyl-L-prolyl-D-alaninamide
SB 75
SB-75
46
MetforminapprovedPhase 31803657-24-914219, 4091
Synonyms:
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
3-(diaminomethylidene)-1,1-dimethylguanidine
657-24-9
AC1L1HE4
AKOS000121065
Apo-Metformin
BIDD:GT0697
BPBio1_000009
BRD-K79602928-003-04-1
BSPBio_000007
BSPBio_002314
C07151
C4H11N5
CAS-1115-70-4
CCRIS 9321
CHEBI:6801
CHEMBL1431
CID4091
D04966
DB00331
DMGG
Diabetosan
Diabex
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
EINECS 211-517-8
Fluamine
Flumamine
Fortamet
Gen-Metformin
Glifage
Gliguanid
Glucophage
Glucophage XR
Glumetza
Glycon
HMS2089D19
HSCI1_000295
Haurymelin
Haurymellin
Islotin
KBio2_002310
KBio2_004878
KBio2_007446
KBio3_002790
KBioGR_002310
 
KBioSS_002312
LA-6023
LS-43899
Melbin
Metformin
Metformin (USAN/INN)
Metformin HCL
Metformin [USAN:INN:BAN]
Metformina
Metformina [DCIT]
Metformina [Spanish]
Metformine
Metformine [INN-French]
Metformine pamoate
Metforminum
Metforminum [INN-Latin]
Metiguanide
MolPort-002-929-560
MolPort-004-288-389
MolPort-005-767-418
Mylan-Metformin
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-Dimethylimidodicarbonimidic diamide
N,N-dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
NCGC00016564-01
NCGC00016564-02
NCGC00016564-03
NNDG
Novo-Metformin
Nu-Metformin
PMS-Metformin
Prestwick0_000004
Prestwick1_000004
Prestwick2_000004
Prestwick3_000004
Ran-Metformin
Ratio-Metformin
Riomet
S2483_Selleck
SPBio_001928
STK011633
Sandoz Metformin
Siofor
T5895664
Teva-Metformin
UNII-9100L32L2N
ZINC12859773
cMAP_000016
metformin
metformin hydrochloride
47
Magnesium oxideapprovedPhase 3641309-48-414792
Synonyms:
 
Magmitt
48
Tadalafilapproved, investigationalPhase 3, Phase 2, Phase 1155171596-29-5110635
Synonyms:
(6R,12AR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R-trans)-6-(1,3-Benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
171596-29-5
1xoz
6-BENZO[1,3]dioxol-5-yl-2-methyl-2,3,6,7,12,12a-hexahydro-pyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
AC1L380B
ADCIRCA
Acdirca
Adcirca
C429886
CHEBI:41488
CHEMBL779
CID110635
CPD000466321
Cialis
Cialis (TN)
Cialis, GF 196960, IC 351, ICOS 351, Tadalafil
D02008
DB00820
FT-0080116
GF 196960
GF-196960
 
HMS2051N17
HSDB 7303
IC 351
IC-351
ICOS 351
Ic351
KS-1117
LS-186558
LS-187015
LS-187770
Lilly brand of tadalafil
MLS000759426
MLS001165782
MLS001195644
MLS001424132
MolPort-002-885-864
S1512_Selleck
SAM001246586
SMR000466321
Tadalafil
Tadalafil (JAN/USAN/INN)
Tadalafil [USAN]
Tadanafil
UNII-742SXX0ICT
ZINC03993855
49
Inulinapproved, nutraceuticalPhase 31069005-80-524763
Synonyms:
(2R,3R,4S,5S,6R)-2-[(2S,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethy
189444-25-5
887747-94-6
AC1L2NNM
AI3-19506
CID24763
DB00638
 
EINECS 232-684-3
INULIN
Inulin USP 27
Inulin [BAN]
Inulin and sodium chloride
Inulin from Jerusalem artichokes
LS-186416
LS-187349
50Botulinum Toxins, Type APhase 3, Phase 2657

Interventional clinical trials:

(show top 50)    (show all 94)
idNameStatusNCT IDPhase
1Multicenter Prospective Study on the Changes of Sexual Function Following Treatment With Alfuzosin (Xatral XL®) in Patients With Benign Prostate HypertrophyCompletedNCT00542165Phase 4
2Safety and Efficacy of QD Versus BID Silodosin With Lower Urinary Tract Symptoms Suggestive of BPHCompletedNCT01260129Phase 4
3Effect of Deep BLock on Intraoperative Surgical ConditionsCompletedNCT01631149Phase 4
4Solifenacin as Add-on Therapy for Overactive Bladder Symptoms in Men Treated for Benign Prostatic HyperplasiaCompletedNCT00771394Phase 4
5Efficacy Study for Use of Dutasteride (Avodart) With Testosterone ReplacementCompletedNCT00752869Phase 4
6Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate CancerCompletedNCT00375765Phase 4
7Effect of Dutasteride on Bladder Wall Hypertrophy in Patients With Benign Prostatic ObstructionCompletedNCT00827814Phase 4
8Benign Prostatic Hyperplasia (BPH) Screening Tool Case Finding Study in Subjects >=50 YearsCompletedNCT02757963Phase 4
9Comparative Efficacy of Dutasteride Plus Tamulosin With Lifestyle Advice Versus Watchful Waiting Plus Lifestyle Advice in the Management of Treatment naïve Men With Moderately Symptomatic Benign Prostatic Hyperplasia and Prostate EnlargementCompletedNCT01294592Phase 4
10Evaluation Of The Efficacy And Safety Of The Doxasozin Gastrointestinal Therapeutic System (GITS) In Patients With Prostate EnlargementCompletedNCT00648323Phase 4
11TRADE-Testosterone Replacement and Dutasteride EffectivenessCompletedNCT00194675Phase 4
12Efficacy of Prunus Domestica Extract in BPHCompletedNCT02702947Phase 4
13Alpha-Blockers in Allergic Rhinitis (MAN 01)CompletedNCT01946035Phase 4
14A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH)Active, not recruitingNCT02656173Phase 4
15Preoperative Administration of Tamsulosin for Prevention of Post Operative Urinary Retention in Males Undergoing Elective Inguinal Hernia RepairEnrolling by invitationNCT02958878Phase 4
16A-botulinic Toxin for Symptomatic Benign Prostate HypertrophyUnknown statusNCT01275521Phase 3
17Cetrorelix Pamoate in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)CompletedNCT00663858Phase 3
18The Safety and Efficacy of Ozarelix to Treat Men With Lower Urinary Tract Symptoms Due to Enlargement of the ProstateCompletedNCT00427219Phase 2, Phase 3
19Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH)CompletedNCT00670306Phase 3
20Medical Therapy of Prostatic Symptoms (MTOPS)CompletedNCT00021814Phase 3
21Clinical Trial in Males With BPH (Enlarged Prostate)CompletedNCT00029822Phase 3
22"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased RiskCompletedNCT00056407Phase 3
23A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary SymptomsCompletedNCT01139762Phase 3
24Intraprostatic Botulinum Toxin Type "A" Injection in Patients With Benign Prostatic Hyperplasia and Unsatisfactory Response to Medical TherapyCompletedNCT01566292Phase 2, Phase 3
25Combination of Metformine/Inulin Versus Metformin on Prostate Benign Hyperplasia in Metabolic SyndromeCompletedNCT02778776Phase 3
26Study to Assess the Efficacy of Medi-Tate TIND DeviceActive, not recruitingNCT02145208Phase 3
27Cetrorelix Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)TerminatedNCT00449150Phase 3
28JALYN for Benign Prostatic Hyperplasia (BPH) and Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)TerminatedNCT01830829Phase 3
29Alfuzosin for Voiding Dysfunction in Multiple Sclerosis (MS)TerminatedNCT00688948Phase 2, Phase 3
30H-36731: Finasteride in Management of Elevated Red Blood CellsWithdrawnNCT02548117Phase 3
31A 20-Week Study of a New Treatment for Men With Benign Prostatic Hyperplasia (BPH).Unknown statusNCT00044226Phase 2
32Vardenafil in Greenlight(TM) Laser Surgery of Benign Prostate HypertrophyCompletedNCT00461123Phase 2
33Effects of Tadalafil Once a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic HyperplasiaCompletedNCT00386009Phase 2
34Safety/Tolerability Study of Alcohol Injection for Treatment of BPH (Enlarged Prostate)CompletedNCT00037141Phase 1, Phase 2
35A Clinical Study to Determine Factors Affecting Absorption and Serum Levels of Lycopene After SupplementationCompletedNCT00154843Phase 2
36Extension Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous ChorioretinopathyCompletedNCT01227993Phase 1, Phase 2
375-Alpha Reductase and Anabolic Effects of TestosteroneCompletedNCT00475501Phase 2
38Oral Androgens in Man-3 (ORAL T-3) Pharmacokinetics of Oral TestosteroneCompletedNCT00161421Phase 2
39Prostate Embolization for Massive Benign Prostatic Hypertrophy (BPH)RecruitingNCT02676544Phase 1, Phase 2
40Use of Autologous Adipose-Derived Stem/Stromal Cells (AD-cSVF) in Symptomatic Benign Prostate HypertrophyRecruitingNCT02961114Phase 1, Phase 2
41Prostate Artery Embolization as a Treatment for Benign Prostatic Hyperplasia in Men With Prostates Larger Than 90 GramsRecruitingNCT02396420Phase 2
42Testosterone Plus Finasteride Treatment After Spinal Cord InjuryRecruitingNCT02248701Phase 2
43Feasibility and Toxicity of Degarelix for Prostate Downsizing Prior to Permanent Seed Prostate BrachytherapyActive, not recruitingNCT01446991Phase 2
44Use of a Novel Radiopaque Embolic Agent in Prostatic Artery Embolisation for Symptomatic Benign Prostatic EnlargementNot yet recruitingNCT03109925Phase 2
45A Study in Men With Benign Prostatic HyperplasiaTerminatedNCT01097707Phase 2
46A Trial to Investigate the Effectiveness and Safety of Org 3236 (Etonogestrel) Tablets in Men With Urinary Complaints Suggestive of a Benign Enlargement of the Prostate (304001)(P05806)TerminatedNCT00651807Phase 2
47Dose Response Study of VA106483 in Males With Nocturia and Benign Prostatic Hypertrophy (BPH)CompletedNCT01330927Phase 1
48Prostate Artery Embolization (PAE) for Treatment of Benign Prostatic HyperplasiaRecruitingNCT02592473Phase 1
49A Clinical Trial to Evaluate the Effects of Food on the Bioavailability of CKD-397 in Healthy Male SubjectsNot yet recruitingNCT02615782Phase 1
50Feasibility Study of Photovaporisation of Prostate With a Limitated Length of Catheterization of 3 HoursUnknown statusNCT02401581

Search NIH Clinical Center for Prostatic Hypertrophy

Inferred drug relations via UMLS68/NDF-RT46:

Genetic Tests for Prostatic Hypertrophy

About this section

Anatomical Context for Prostatic Hypertrophy

About this section

MalaCards organs/tissues related to Prostatic Hypertrophy:

36
Prostate, Heart, Kidney, Breast, Appendix, Colon, Smooth muscle

Publications for Prostatic Hypertrophy

About this section

Articles related to Prostatic Hypertrophy:

(show top 50)    (show all 534)
idTitleAuthorsYear
1
Prostate Artery Embolization for Complete Urinary Outflow Obstruction Due to Benign Prostatic Hypertrophy. (27853823)
2017
2
Treatment of lower urinary tract symptoms in benign prostatic hypertrophy with I+-blockers. (27629686)
2016
3
Re: Stroke Associated with Alpha Blocker Therapy for Benign Prostatic Hypertrophy. (27321530)
2016
4
Inhibitory Activities of Phenolic Compounds Isolated from Adina rubella Leaves Against 5I+-Reductase Associated with Benign Prostatic Hypertrophy. (27399661)
2016
5
The Impact of Medical and Surgical Treatment for Benign Prostatic Hypertrophy on Erectile Function. (26438220)
2015
6
Kidney transplant complications from undiagnosed benign prostatic hypertrophy. (25832848)
2015
7
Supplementary management of benign prostatic hypertrophy with Prostaquil. An 8-week registry. (26492588)
2015
8
Clinical Outcomes of Transurethral Enucleation with Bipolar for Benign Prostatic Hypertrophy. (26662662)
2015
9
Effects of I+-blocker therapy on active duty military and military retirees for benign prostatic hypertrophy on diabetic complications. (25735029)
2015
10
The Role of Minimally Invasive Surgical Techniques in the Management of Large-gland Benign Prostatic Hypertrophy. (26543428)
2015
11
Varicocele: the origin of benign prostatic hypertrophy? Testosterone dosages in the periprostatic plexus. (26290288)
2015
12
Tadalafil and benign prostatic hypertrophy. Too risky. (24860894)
2014
13
Efficacy of Long-Term Daily Dosage of Alfuzosin 10 mg upon Sexual Function of Benign Prostatic Hypertrophy Patients: Two-Year Prospective Observational Study. (25606561)
2014
14
Surgical therapy for benign prostatic hypertrophy/bladder outflow obstruction. (24744521)
2014
15
Bilateral ureteral obstruction revealing a benign prostatic hypertrophy: a case report and review of the literature. (24513237)
2014
16
Re: a phase II randomised double-blind placebo-controlled clinical trial investigating the efficacy and safety of ProstateEZE Max: a herbal medicine preparation for the management of symptoms of benign prostatic hypertrophy. (25629105)
2014
17
Bipolar transurethral resection versus monopolar transurethral resection for benign prostatic hypertrophy: a systematic review and meta-analysis. (24754254)
2014
18
Estrogen receptor beta agonist LY500307 fails to improve symptoms in men with enlarged prostate secondary to benign prostatic hypertrophy. (25348255)
2014
19
Re: Editorial comment on constitutional, organopathic and combined homeopathic treatment of benign prostatic hypertrophy: a clinical trial: S. A. Kaplan J Urol 2013; 190: 1818-1819. (24892642)
2014
20
Preparation, characterization and stability study of dutasteride loaded nanoemulsion for treatment of benign prostatic hypertrophy. (25587300)
2014
21
Successful minimally-invasive management of a case of giant prostatic hypertrophy associated with recurrent nephrogenic adenoma of the prostate. (23565707)
2013
22
Re: Constitutional, organopathic and combined homeopathic treatment of benign prostatic hypertrophy: a clinical trial. (24120797)
2013
23
A phase II randomised double-blind placebo-controlled clinical trial investigating the efficacy and safety of ProstateEZE Max: a herbal medicine preparation for the management of symptoms of benign prostatic hypertrophy. (23642948)
2013
24
Alpha-1 adrenergic antagonists in aircrew for the treatment of benign prostatic hypertrophy. (23305000)
2013
25
Correlation of transrectal and transabodominal ultrasound measurement of transition zone volume with post-operative enucleated adenoma volume in benign prostatic hypertrophy. (24876907)
2013
26
American Urological Association and European Association of Urology guidelines in the management of benign prostatic hypertrophy: revisited. (22123290)
2012
27
Constitutional, organopathic and combined homeopathic treatment of benign prostatic hypertrophy: a clinical trial. (23089217)
2012
28
Sphaeranthus indicus attenuates testosterone induced prostatic hypertrophy in albino rats. (21503998)
2011
29
The early days of prostatectomy for benign prostatic hypertrophy. (22132481)
2011
30
Carvedilol for the treatment of benign prostatic hypertrophy in patients with heart failure? (21962427)
2011
31
Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy: a randomised controlled study. (21171937)
2011
32
Association of Polymorphisms in the Prostate-Specific Antigen (PSA) Gene Promoter with Serum PSA Level and PSA Changes after Dutasteride Treatment in Korean Men with Benign Prostatic Hypertrophy. (21221201)
2010
33
Serenoa repens in benign prostatic hypertrophy: analysis of 2 Italian studies. (20944533)
2010
34
Effect of Benincasa hispida fruits on testosterone-induced prostatic hypertrophy in albino rats. (24688153)
2010
35
Acute colonic obstruction due to benign prostatic hypertrophy. (19405320)
2009
36
Impact of alpha 1-adrenergic antagonist use for benign prostatic hypertrophy on outcomes in patients with heart failure. (19576359)
2009
37
Oxidative stress in prostate hypertrophy and carcinogenesis]. (19644150)
2009
38
Increased frequency and nocturia in a middle aged male may not always be due to Benign Prostatic Hypertrophy (BPH): a case report. (19946479)
2009
39
Management of benign prostatic hypertrophy-related urinary retention: current trends and perspectives. (20027550)
2009
40
Benign prostatic hypertrophy. (19737273)
2009
41
Pharmacological management of benign prostatic hypertrophy with phosphodiesterase-5 inhibitors. (20017412)
2009
42
Transurethral resection of the prostate (TURP)--in the treatment of benign prostatic hypertrophy (BPH) in Mekelle, Ethiopia. (19743783)
2009
43
Increased frequency and nocturia in a middle aged male may not always be due to benign prostatic hypertrophy: a case report. (20184712)
2009
44
Characteristic gene expression profiles of benign prostatic hypertrophy and prostate cancer. (19639170)
2009
45
Tamsulosin oral controlled absorption system (OCAS) in the treatment of benign prostatic hypertrophy. (18728700)
2008
46
5-Alpha reductase inhibitors--benign prostatic hypertrophy and much more]. (18570285)
2008
47
Influence of dihydrotestosterone deficit on treatment of prostatic diseases regarding to contemporary methods of prostatic hypertrophy treatments]. (19205388)
2008
48
Testosterone levels in benign prostatic hypertrophy and prostate cancer. (18362481)
2008
49
Medical management of benign prostatic hypertrophy. (18163946)
2007
50
Incontinence related to management of benign prostatic hypertrophy. (18179990)
2007

Variations for Prostatic Hypertrophy

About this section

Expression for genes affiliated with Prostatic Hypertrophy

About this section
Search GEO for disease gene expression data for Prostatic Hypertrophy.

Pathways for genes affiliated with Prostatic Hypertrophy

About this section

GO Terms for genes affiliated with Prostatic Hypertrophy

About this section

Biological processes related to Prostatic Hypertrophy according to GeneCards Suite gene sharing:

(show all 14)
idNameGO IDScoreTop Affiliating Genes
1androgen metabolic processGO:000820910.5CYP19A1, ESR1
2prostate gland growthGO:006073610.4AR, CYP19A1
3tertiary branching involved in mammary gland duct morphogenesisGO:006074810.4AR, PGR
4sex differentiationGO:000754810.3AR, SRY
5positive regulation of phosphorylationGO:004232710.2AR, EGF
6steroid hormone mediated signaling pathwayGO:004340110.0AR, ESR1, PGR
7positive regulation of mitotic nuclear divisionGO:00458409.9EGF, FGF8
8mammary gland alveolus developmentGO:00607499.9AR, EGF, ESR1
9uterus developmentGO:00600659.8CYP19A1, ESR1
10transcription initiation from RNA polymerase II promoterGO:00063679.8AR, ESR1, PGR
11positive regulation of MAPK cascadeGO:00434109.7ADRA1A, AR, CD36
12positive regulation of cytosolic calcium ion concentrationGO:00072049.7ADRA1A, CD36, ESR1
13negative regulation of gene expressionGO:00106299.6CD36, ESR1, PGR
14positive regulation of ERK1 and ERK2 cascadeGO:00703749.5ADRA1A, CD36, FGF8

Molecular functions related to Prostatic Hypertrophy according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1ATPase bindingGO:005111710.1AR, ESR1, PGR
2RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA bindingGO:00048799.9AR, ESR1, PGR
3steroid bindingGO:00054969.9AR, ESR1, PGR
4steroid hormone receptor activityGO:00037079.4AR, ESR1, PGR
5lipid bindingGO:00082899.2AR, CD36, ESR1, PGR

Sources for Prostatic Hypertrophy

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet